At a glance
ClinicalIndex Comparison RecordN/AUnknown· 236 enrolled
Drug / intervention
PAXMAN Orbis Scalp Cooler +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Scalp Cooling for Alopecia Prevention (SCALP)
In Brief
A clinical study evaluating PAXMAN Orbis Scalp Cooler and Control No treatment for Breast Cancer and Alopecia. Targeting 236 participants across 7 sites.
Detailed Summary
Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Alopecia
CountriesUnited States
Collaborators--
Timeline
N/AUnknownOverdue
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartMay 2014
Primary CompletionFeb 2017
Study CompletionDec 2022
TodayJul 2026
First PostedNov 18, 2013
Enrollment StartMay 15, 2014
Primary CompletionFeb 10, 2017
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.6 years ago
Interventions
PAXMAN Orbis Scalp Coolerdevice
Treatment with Orbis scalp cooling cap
Control No treatmentother
No treatment to prevent hair loss